
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience Corp has demonstrated a strong positive outlook through its improved financial guidance, raising its gross margin expectation for FY25 to 49.5% and projecting the exit of FY25 with margins exceeding 50%. Additionally, the company has reiterated its revenue guidance while also increasing expectations for adjusted EBITDA, indicating stronger operational performance ahead. The anticipated spin-off is expected to enhance visibility to adjusted EBITDA profitability, further reinforcing the company's financial stability and growth potential.
Bears say
Twist Bioscience Corp faces significant financial challenges, as its data business has consistently been a headwind, negatively impacting its adjusted EBITDA by approximately $5 million per quarter. This ongoing burden suggests persistent operational inefficiencies within that segment, which could hinder overall profitability. Furthermore, the reliance on a limited revenue source primarily from the United States may exacerbate vulnerabilities, contributing to a negative outlook for the company’s stock performance.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares